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Abstract
Background:  Osteopontin (OPN), a secreted phosphoglycoprotein, has been strongly
associated with tumor progression and aggressive cancers. MDA-MB-435 cells secrete very high
levels of OPN. However metastasis-suppressed MDA-MB-435 cells, which were transfected
with breast cancer metastasis suppressor 1 (BRMS1), expressed significantly less OPN. BRMS1
is a member of mSin3-HDAC transcription co-repressor complex and has been shown to
suppress the metastasis of breast cancer and melanoma cells in animal models. Hence we
hypothesized that BRMS1 regulates OPN expression.
Results:  The search for a BRMS1-regulated site on the OPN promoter, using luciferase
reporter assays of the promoter deletions, identified a novel NF-κB site (OPN/NF-κB).
Electrophoretic mobility shift assays and chromatin immunoprecipitations (ChIP) confirmed this
site to be an NF-κB-binding site. We also show a role of HDAC3 in suppression of OPN via
OPN/NF-κB.
Conclusion: Our results show that BRMS1 regulates OPN transcription by abrogating NF-κB
activation. Thus, we identify OPN, a tumor-metastasis activator, as a crucial downstream target
of BRMS1. Suppression of OPN may be one of the possible underlying mechanisms of BRMS1-
dependent suppression of tumor metastasis.
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Background
Several reports have linked the phosphoglycoprotein,
osteopontin (OPN), with tumor progression and meta-
static spread [1-4]. The levels of OPN are significantly ele-
vated in the tumors and plasma of patients with
metastatic breast cancer and are notably associated with
tumor aggressiveness and decreased patient survival [1,2].
Alterations in the gene expression profile upon OPN over-
expression in a breast cancer cell line include changes in
genes classically associated with early stages of tumor for-
mation [5]. We have recently found that OPN contributes
to early breast tumor development [6].
Breast cancer metastasis suppressor 1 (BRMS1) has been
shown to suppress metastasis of metastatic human breast
cancer and melanoma lines as well as mouse mammary
cancers [7-9]. BRMS1 is a member of the mSin3-HDAC
transcription co-repressor complex [10]. This finding sug-
gests that BRMS1 may modulate expression of other
genes. Hence, we were interested in investigating the
downstream signaling modulated by BRMS1. We present
evidence that expression of tumor/metastasis promoting
OPN is downregulated by BRMS1. We describe a novel
NF-κB site in the OPN promoter and show that BRMS1
interferes with the activation of NF-κB leading to the sup-
pression of OPN. We also show a role of HDAC3 in sup-
pression of OPN via OPN/NF-κB.
Results
BRMS1 suppresses OPN expression
Restoration of BRMS1 expression in the metastatic breast
cancer cell line MDA-MB-435 (435) suppresses its meta-
static capability in nude mice [7]. Gene expression analy-
sis revealed that the expression of OPN was down-
regulated by 95% in the 435/BRMS1 cells compared to
vector-transfected 435 cells. We confirmed this observa-
tion by an immunoblot analysis of the conditioned cell-
free, serum-free supernatant from the two cell lines. We
saw a dramatic reduction in the level of secreted OPN
from 435/BRMS1 cells (Fig. 1A) as well as decreased
expression of OPN in the cell lysate (data not shown).
Consistent with these findings, we saw that the 435/
BRMS1 cells were only marginally (15–20% of the con-
trol) able to activate the luciferase reporter of OPN pro-
moter (Fig. 1B).
The OPN promoter construct lacking the NF-κB site is 
relieved for suppression by BRMS1
Intron 1 of OPN has been implicated in OPN regulation
[11]. Hence, we constructed OPN-∆I1 which lacked +113
to +325 region, downstream of the transcription start site.
This construct was relieved of BRMS1 repression (Fig. 2A).
Analysis of this region using Transfac [12] showed a puta-
tive NF-κB site at the +124 to +136 position. A deletion of
the OPN promoter, OPN-NF (lacking +209 to +325),
which has an intact NF-κB site, remained sensitive to sup-
pression by BRMS1. This suggests that BRMS1 may func-
tion  via  this putative NF-κB site to suppress OPN. To
confirm this, we created OPN/NotI, in which the NF-κB
site is abolished by inserting a NotI site in its place. OPN/
NotI  is refractory to suppression by BRMS1 (Fig. 2A),
thereby substantiating the observations made earlier.
Of note, the two deletion constructs (OPN-NF and OPN-
∆I1) have overall lower promoter activity. This is not
unexpected since deletions in this region of OPN pro-
moter have previously been reported to have such an
effect [11].
Recombinant p65 and p50 bind to and retard the mobility 
of the predicted NF-κB binding site from the OPN 
promoter
The predicted OPN/NF-κB site has 9 conserved and 3 non-
conserved bases as compared to a consensus NF-κB bind-
ing site (Figure 2B). Hence, to investigate whether this site
is recognized by the prototypical members of the NF-κB
complex (p65 and p50), we performed an EMSA using
double-stranded oligos coding for OPN/NF-κB as well as
mutant OPN/NF-κB. As seen in lanes 2 and 5, we
observed a shift in probe with recombinant human p50
and p65, respectively (Fig. 2B). An anti-p65 antibody
caused a supershift of the probe when incubated with
recombinant p65 (Lane 6). The gel mobility of the probe
was also retarded by the nuclear extract of 435 cells (Lane
3), which was completely out-competed by an unlabeled
('cold') consensus NF-κB probe (Lane 4). Notably, 435
has constitutively active nuclear NF-κB (p65 and p50)
[13]. Hence, this shift confirms that the resident members
of NF-κB complex from 435 cells recognize the OPN/NF-
κB cis element. The mutant OPN/NF-κB probe does not
show a shift with p65 and p50 (Lanes 8 and 9).
NF-κB subunits bind to the OPN promoter in vivo in MDA-
MB-435
By ChIP assays using anti-p65 and -p50 in MDA-MB-435
cells, we were able to amplify the 201 bp target region
from the OPN promoter by PCR (Fig. 2C). The intensity
of the band obtained by ChIP using the p50 antibody was
consistently lower in multiple repeats. This could be due
to weaker immunoprecipitations by the p50 antibody or
weaker interaction of p50 with OPN/NF-κB as compared
to that of p65. A control PCR designed to amplify a 151
bp region (that lacks any homology to NF-κB site), 1575
bp upstream of the OPN/NF-κB site did not yield a prod-
uct following ChIP using the p65 or p50 antibody (data
not shown). Thus, ChIP specifically pulled down the NF-
κB-binding site from the OPN promoter.Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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A. Expression of OPN is down-regulated by 95% in the 435/BRMS1 cells Figure 1
A. Expression of OPN is down-regulated by 95% in the 435/BRMS1 cells. Serum-free conditioned medium from equal numbers 
of pcDNA transfected MDA-MB-435 (V) and 901-BRMS1-transfected 435 cells, 435/BRMS1 (BRMS1) was resolved using a 
12.5% SDS-PAGE, transferred to a PVDF membrane and probed with the anti-human OPN monoclonal antibody [30]. The bar 
graph depicts the percent change in OPN expression based on densitometric analysis of the immunoblot. To confirm the 
BRMS1 expression in these cells, the cells were lysed in NP-40 lysis buffer and 30 ug of protein was resolved using a 12.5% 
SDS-PAGE, transferred to a PVDF membrane and probed with the anti-901 monoclonal antibody (for BRMS1 epitope). The 
membrane was reprobed for levels of β-actin to confirm equal loading. B. BRMS1 suppresses activity of the human OPN pro-
moter. COS-7 cells were co-transfected with pGL3-OPN [28] and pCMV-myc or pCMV-myc-BRMS1 using Lipofectamine 
2000 (Invitrogen). Luciferase activity was normalized to the total protein concentration. Data is expressed as Relative luci-
ferase activity, where control is 100%. The data represents five independent experiments in triplicate. * indicates significant 
suppression (p < 0.05).Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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A. The OPN promoter lacking the NF-κB site is relieved for BRMS1 suppression Figure 2
A. The OPN promoter lacking the NF-κB site is relieved for BRMS1 suppression. The grey box represents the predicted NF-
κB site. The dotted line indicates the region deleted in the construct. OPN-∆I1 does not have the NF-κB-binding site and is not 
suppressed by BRMS1. OPN/NotI, in which the NF-κB site is abolished by inserting a NotI site in its place, is refractory to sup-
pression by BRMS1. Data is expressed as Relative luciferase activity of control, where control (pGL3-OPN) is 100%. The data 
shown represents more than three independent experiments in triplicate. * indicates significant suppression, p value < 0.05 and 
** indicates p < 0.01 compared to respective controls. B. Recombinant p65 and p50 bind to and retard the mobility of the pre-
dicted NF-κB site from the promoter of OPN. Lane 1: Probe bearing the NF-κB site from OPN promoter; Lane 2: Probe + 
recombinant p50; Lane 3: Probe + nuclear extract of MDA-MB-435; Lane 4: Probe + unlabeled 'cold' consensus probe + 
Nuclear extract of MDA-MB-435; Lane 5: Probe + recombinant p65; Lane 6: Probe + recombinant p65 + anti-p65 antibody; 
Lane 7: Mutant probe; Lane 8: Mutant Probe + recombinant p65; Lane 9: Mutant Probe + recombinant p50. The box gives the 
sequence comparison of the OPN/NF-κB with the consensus NF-κB-binding site. The underscored bases in OPN/NF-κB rep-
resent variation from the consensus. Mutant OPN/NF-κB (Mut OPN/NF-κB) is also shown with the mutations represented in 
bold lower case. C. NF-κB subunits bind to the OPN promoter in vivo. MDA-MB-435 cells were fixed with formaldehyde, 
lysed, and then sonicated. In vivo cross-linked chromatin was then precipitated independently using p65 (Anti-p65), p50 (Anti-
p50), normal rabbit IgG (Rabbit), no antibody, or Positive and Negative kit control antibodies (Active Motif). The recovered 
immunoprecipitated DNA was then used for PCR with primers specific for the OPN/NF-κB-containing promoter segment. A 
151 bp product corresponding to a region 1575 bp upstream of the OPN/NF-kB site (that lacks a predicted NF-κB site [12]) 
was absent in a control PCR following ChIP Primers: 5'-TTCCCCCTACCAAATGTTCA-3' and 5'-TGCTGCAAAAGTAATT-
GTGGTT-3'.Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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OPN/NF-κB grafting renders SV40 promoter sensitive to 
BRMS1 suppression
If the OPN/NF-κB site is recognized by BRMS1, grafting it
onto another promoter should render that promoter sen-
sitive to BRMS1 repression. We grafted three tandem
repeats of OPN/NF-κB (3XOPN/NF-κB) upstream of the
SV40 promoter in pGL3-Control vector to generate pGL3-
3XOPN/NF-κB. The luciferase reporter assays showed that
pGL3-3XOPN/NF-κB is significantly (p < 0.01) repressed
by BRMS1 (Fig. 3A). This observation implies that the
OPN/NF-κB site is sensitive to BRMS1.
The OPN promoter construct lacking NF-κB is relieved for 
suppression by HDAC3
HDAC3 is reported to regulate the acetylation status and
transcriptional activity of p65 [14]. Therefore, we evalu-
ated the luciferase activity of full length OPN promoter
(pGL3-OPN), the deletion of the OPN promoter with
intact NF-κB site (OPN-NF) and the OPN promoter with
a deletion of NF-κB site (OPN-∆I1), in the presence and
absence of HDAC3. We observed that the OPN and OPN-
NF promoter activity is repressed by HDAC3 (Fig. 3B).
Interestingly, the deletion of the OPN promoter (OPN-
∆I1) that was refractory to BRMS1-mediated suppression
was also not suppressed by HDAC3. This was also con-
firmed with the OPN/NotI construct (in which the NF-κB
site is abolished by inserting a NotI site in its place, with-
out changing the length of the construct), which also is
refractory to suppression by HDAC3. This suggested that
HDAC3 represses OPN through the same cis-site as
BRMS1.
BRMS1 associates with HDAC3
We co-transfected COS-7 cells with FLAG-HDAC3 and
myc-BRMS1 expressing plasmids. We were able to co-
immunoprecipitate BRMS1 from the lysate using anti-
FLAG antibody (Fig. 4A). This observation corroborates
with the recently published literature showing that
BRMS1 associates with Class I and II HDAC members
[15].
BRMS1 reduces acetylation of p65
MDA-MB-435 has a significant amount of HDAC3. How-
ever, it shows constitutive NF-κB with acetylated p65.
Since we know from our previous work [7] that these cells
do not have significant levels of BRMS1, we tested if re-
expressing BRMS1 could influence the acetylation status
of p65 in these cells. We immunoprecipitated p65 from
435 cells with and without BRMS1 and immunoblotted
with anti-acetyl lysine antibody. We saw that in 435/
BRMS1 cells, the otherwise constitutively active
(acetylated) p65 had reduced acetylation despite having
levels of p65 comparable with the control 435 cells (Fig.
4B).
Discussion
BRMS1 has been implicated in several molecular events
such as restoration of gap-junctional intracellular com-
munication [16] and phosphoinositide signaling [17].
Cicek et al [18] have demonstrated that BRMS1 expression
leads to the inhibition of IκBα phosphorylation and deg-
radation and subsequently to a reduction of p65 and p50
nuclear translocation. Very recently, Liu et al [19] have
demonstrated involvement of BRMS1 in mediating
acetylation of NF-κB. Our study has demonstrated a
known metastasis promoting gene, OPN, to be directly
regulated by BRMS1, a metastasis suppressor gene. We
observe consistent suppression of OPN by BRMS1 at the
RNA and protein level, corroborating our reporter assays
using the OPN promoter which show suppression by
BRMS1. Further investigations demonstrate that the site
responsible for BRMS1-mediated repression of OPN
matches closely to an NF-κB consensus site. Interestingly,
this site is located after the transcription start site, within
intron 1 of OPN. It is known that intron 1 of the OPN
gene contains crucial regulatory elements that can influ-
ence gene expression [11]. NF-κB is also reported to regu-
late several genes through cis-acting elements located in
the first intron [20,21]. There are several NF-κB family
members that participate in the formation of different
homo- or heterodimers with various degrees of target gene
specificity [22]. We have analyzed the prototypical NF-κB
complex, which is a heterodimer of p50 and p65 (RelA).
Gel shift assays using purified human p65 and p50 con-
firmed a direct recognition of the OPN/NF-κB site by the
NF-κB complex members. The ChIP assay demonstrated
that the OPN/NF-κB site is indeed functional in vivo. The
studies with mutated OPN/NF-κB (in EMSA) as well as a
'grafted' NF-κB site support these findings. More interest-
ingly, we observed that HDAC3 controls the OPN expres-
sion through the OPN/NF-κB site. Co-
immunoprecipitation studies indicate that BRMS1 is
capable of interacting with HDAC3. It is known that
HDAC3 deacetylates p65 resulting in decreased activity of
NF-κB [14]. Our studies showed that restoration of
BRMS1 expression in MDA-MB-435 cell line, which has
constitutively acetylated p65 despite significant levels of
HDAC3, leads to deacetylation of p65. This results in the
inactivation of NF-κB, which is reflected in decreased
expression of the target gene, OPN. It is possible that the
BRMS1-mediated reduction of OPN expression is due to
either reduction in p65 trans-activation or due to
decreased binding of NF-κB to the OPN/NF-κB site.
BRMS1 is a known member of the mSin3-HDAC tran-
scription co-repressor complex [10]. Thus, it is expected to
interact with HDAC 1 and 2. Since HDAC3 is not a known
member of the mSin3-HDAC complex, our work pre-
sented here implies the involvement of BRMS1 in other
HDAC-containing complex(es).Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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A. BRMS1 downregulates OPN via the NF-κB site Figure 3
A. BRMS1 downregulates OPN via the NF-κB site. A reporter plasmid bearing three NF-κB sites from the OPN promoter, 
pGL3-3XOPN/NF-κB, upstream of the SV40 promoter or pGL3-control was co-transfected with pCMV-mycBRMS1 into 
COS-7 cells. Luciferase activity from this reporter construct was measured. The experiment was repeated thrice in triplicate.* 
indicates significant suppression compared with respective controls (p < 0.05). B. The OPN promoter lacking an intact NF-κB 
site is relieved for suppression by HDAC3. The OPN promoter construct, pGL3-OPN, and its deletions, OPN-NF (retains the 
NF-κB-binding site) and OPN-∆I1 (lacks the NF-κB-binding site) and the OPN/NotI construct (OPN/NF-κB site is replaced 
with a NotI site) were co-transfected with pcDNA3 or pcDNA3-FLAG-HDAC3 in COS-7 cells and monitored for the effect of 
HDAC3 on the promoter activity of OPN. The results shown represent the experiment done twice in triplicate. * indicates 
significant suppression compared with respective controls (p < 0.05).Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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OPN is an important chemokine, promoter of tumor pro-
gression, and indicator of poor prognosis in a variety of
cancers [5]. Work by Renault et al has implicated NF-κB
regulation of OPN [23]. The NF-κB pathway is one of the
major signaling pathways responsible for cancer cell inva-
sion and as targets for cancer therapy. Constitutive activa-
tion of NF-κB, such as in MDA-MB-435, is observed
during progression of breast cancer to hormone-inde-
pendent growth [14]. Our findings suggest that BRMS1 is
able to deactivate this NF-κB by deacetylation of p65 pos-
sibly by its association with HDAC3.
Conclusion
BRMS1 has been shown to suppress metastasis of breast
cancer and melanoma in animal model studies. Also,
BRMS1 is a member of mSin3-HDAC transcription co-
repressor complex. Our work demonstrates that expres-
sion of osteopontin, a tumor-metastasis promoting pro-
tein, is regulated by BRMS1. We also demonstrate that this
regulation is brought about by abolishing NF-κB activa-
tion of OPN promoter. We also show that the OPN pro-
moter is sensitive to repression by HDAC3 via the OPN/
NF-κB site. Our studies imply that BRMS1 likely sup-
presses OPN by abrogating activation of NF-κB. Thus,
downregulation of OPN may be one of the mechanisms
of metastasis suppression by BRMS1.
Materials and methods
Cell lines
MDA-MB-435 (referred to as 435), a gift from Dr. Janet
Price (University of Texas-M. D. Anderson Cancer Center)
is a human metastatic breast carcinoma cell line [24].
(Note: There is a debate about the origin of this cell line
(melanoma or breast cancer) [25-27], however BRMS1
has been shown to suppress metastasis of both these can-
cers. Hence we used this cell line as it is the best model for
the regulation study of OPN. BRMS1-transfected 435
(435/BRMS1) were generated by us and the culture condi-
tions have been described previously [7]. For all func-
tional and biological assays, cells with >95% viability
were used at 70–90% confluence. All the lines were rou-
tinely checked and found negative for Mycoplasma spp.
using the TaKaRa Mycoplasma detection kit (TaKaRa Bio,
Otsu, Shiga, Japan).
Plasmids and transfections
pCMV-myc-BRMS1 was constructed by cloning the
BRMS1 ORF in pCMV-myc (BD-Clontech, CA, Palo Alto,
USA). The human OPN promoter construct was a gift
from Dr. Iizuka, Hokkaido University, Japan [28]. PCR-
generated deletions of the OPN promoter (indicated in
Fig.2A) were cloned in the pGL3-basic vector (Promega,
Madison, WI, USA).  A 3XOPN/NF-κB construct, pGL3-
3XOPN/NF-κB, was made by cloning commercially syn-
thesized oligomers bearing the OPN/NF-κB site repeated
three times in tandem into pGL3-Control vector
(Promega). The NF-κB site in the OPN promoter was dis-
rupted and replaced with a NotI site (OPN/NotI) using the
oligos 5'-GATCGATCGTGCGGCCGCAAATTCTAAG-
GAAAAATATTTTTAATTGTAATGCTG-3' and 5'-
GATCGATCGTGCGGCCGCATGTTTTTCAGCTGAAT-
GCACAAC-3' with pGL3-OPN as a template for inside-out
PCR.
The pcDNA3-FLAG-HDAC3 plasmid was a gift from Dr.
Edward Seto, University of South Florida, FL, USA [29].
Immunoblotting
To determine OPN expression, 4 × 106 cells were seeded in
5% FBS containing medium. After 24 hours, the medium
A. BRMS1 co-immunoprecipitates HDAC3 Figure 4
A. BRMS1 co-immunoprecipitates HDAC3. FLAG-HDAC3 
was co-transfected into COS-7 cells with either pCMV-myc 
(V) or pCMV-myc-BRMS1(B) using Lipofectamine 2000 (Inv-
itrogen). The cell lysate was immunoprecipitated with 1 µg 
anti-FLAG Ab (Sigma). The precipitated proteins were 
resolved by SDS-PAGE and immunoblotted with 1:500 dilu-
tion anti-myc Ab (BD Clontech). Independently the cell 
lysate was immunoblotted with anti-FLAG antibody to con-
firm expression of FLAG-HDAC3. B. BRMS1 reduces 
acetylation of p65. MDA-MB-435 cells were transfected with 
pCMV-myc (V) or pCMV-myc-BRMS1 (B) and immunopre-
cipitated with anti-p65 antibody. The immunoprecipitate was 
resolved on SDS-PAGE, transferred to PVDF membrane and 
immunoblotted with anti-acetyl lysine antibody. The lysate 
shows that the levels of p65 are not altered by BRMS1.Molecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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was replaced with serum-free medium and assayed 24
hours later for OPN expression. The cell-free medium was
resolved using a 12.5% SDS-PAGE. Proteins were trans-
ferred to a PVDF membrane and probed with the anti-
human OPN mouse monoclonal antibody [30] (1:1000)
followed by secondary antibody conjugated to horserad-
ish peroxidase (Amersham Biosciences, Piscataway, NJ,
USA) and detected using chemiluminescence (Amersham
BioSciences). OPN is seen at ~55–65 kDa. Cell lysates
were prepared as described previously [10] and 30 µg was
resolved using a 12.5% SDS-PAGE and immunoblotted
with the respective primary antibody followed by detec-
tion using Supersignal West Dura (Pierce, Rockford, IL,
USA). Epitope-tagged BRMS1 expression from 435/
BRMS1 was detected using anti-901 epitope tag antibody,
described previously by us [7]. Densitometric analysis was
performed using the digital densitometry analysis tool of
AlphaEase®FC image analysis software.
Immunoprecipitation
COS-7 cells were co-transfected with pCMV-myc-BRMS1
and pcDNA3-FLAG or pcDNA3-FLAG-HDAC3 using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) per
the manufacturer's instructions. Transfected cells were
lysed and immunoprecipitated with 1 µg anti-FLAG Ab
(Sigma) and immunoblotted as described above. The
membrane was probed with 1:500 dilution anti-myc Ab
(BD Clontech, Palo Alto, CA, USA). For analysis of the
acetylation status of p65, 300 µM Trichostatin A (Calbio-
chem, EMD Biosciences, La Jolla, CA) was added to the
lysis buffer to halt HDAC activity released upon cell lysis.
The cell lysate was immunoprecipitated with the anti-p65
antibody (Santa Cruz) followed by the rabbit anti-acetyl
lysine antibody (1:1000) (Chemicon, Temecula, CA,
USA) for immunodetection.
Luciferase reporter assays
COS-7 cells were transfected using Lipofectamine 2000
(Invitrogen) per the manufacturer's instructions. Total
protein was harvested (Luciferase assay kit, Promega) and
the luciferase activity measured using a Turner 20/20
luminometer (Turner Biosystems, Sunnyvale, CA, USA).
The luciferase reading was normalized to the total protein
concentration. Data is expressed as Relative luciferase
activity, where control is 100%.
Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were isolated from MDA-MB-435 cells
grown until approximately 85% confluent in a 100 mm
dish using the protocol of Zayzafoon, et al [31]. Binding
reactions containing either 10 µg nuclear extract or 100 ng
or 66 ng, respectively, of recombinant p65 (Active Motif,
Carlsbad CA) or p50 (Promega), 1 µg poly (dI-dC), and
20 fmol biotinylated oligonucleotide probe in buffer (10
mM Tris, 50 mM KCl, 1 mM DTT, 5 mM MgCl2) were
incubated at room temperature for 30 minutes.
The oligonucleotide probes correspond to the OPN/NF-
κB site (5'-GAATTTCATGGGGAAGTCCAAATTCTAAG) or
Mut OPN/NF-κB (5'-GAATTTCATGCGGACTTCGAAAT-
TCTAAG).
A consensus NF-κB probe (5'-AGTTGAGGGGACTTTC-
CCAGGC) served as a specific inhibitor. For antibody
supershift, the samples were preincubated with 2 µg of
anti-p65 antibody (Santa Cruz). Gel electrophoresis, blot-
ting and development followed the manufacturer's proto-
col of the Chemiluminescent LightShift Assay Kit (Pierce).
Four pmol of the consensus NF-κB probe (5'-AGTTGAG-
GGGACTTTCCCAGGC) served as a specific cold compet-
itor.
Chromatin immunoprecipitation
Cells (435) were utilized for chromatin immunoprecipita-
tion using the ChIP-IT kit (Active Motif) as directed by the
manufacturer using p65 or p50 antibody. Parallel controls
for each experiment included samples with no chromatin,
no antibody, normal rabbit IgG (Santa Cruz Biotech), and
the kit-provided positive (RNA polymerase II) and nega-
tive control antibodies. After elution and purification, the
recovered immunoprecipitated DNA samples were used
for PCR (Platinum Taq polymerase; Invitrogen) using
primers [5'-CAGTTGCAGCCTTCTCAGC-3' (forward) and
5'-CCTTTGTTCCACAGGAGACC-3' (reverse)] to amplify
a 201 bp segment of the OPN promoter containing the
NF-κB site. PCR products were analyzed by agarose gel
electrophoresis.
The specificity of the pull-down was confirmed by ampli-
fying a region 1575 bp upstream from the PCR product
containing the NF-kB site tested. The primers used were 5'-
TTCCCCCTACCAAATGTTCA-3' and 5'-TGCTGCAAAAG-
TAATTGTGGTT-3'. The PCR generates a 151 bp product.
This segment lacks a predicted NF-κB site [12].
Statistical analysis
Statistical analysis was done using the unpaired one-tailed
Student's t-test (Graphpad Prism, San Diego, CA, USA).
Abbreviations
BRMS1 Breast cancer Metastasis Suppressor 1
ChIP Chromatin Immunoprecipitation
DMEM-F12 Dulbecco's Modified Eagle's Medium:F12
medium (1:1)
EMSA Electrophoretic mobility shift assayMolecular Cancer 2007, 6:6 http://www.molecular-cancer.com/content/6/1/6
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HDAC Histone deacetylase
ORF Open reading frame
OPN Osteopontin
PCR Polymerase chain reaction
PVDF Polyvinylidine fluoride
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